Targeting cancer drivers to improve treatment outcomes
Targeting Oncogenic Drivers in Cancer
This study is exploring new treatments for breast cancer that is driven by estrogen and has become resistant to standard therapies, focusing on creating special small molecules that can target and kill cancer cells with certain gene mutations, especially for patients who have cancer that has spread to the brain.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11012866 on NIH RePORTER |
What this research studies
This research focuses on developing new therapies for estrogen receptor alpha (ERα)-positive breast cancer, which is known for its resistance to current treatments. The approach involves creating novel small molecules that can effectively kill cancer cells with specific mutations in the ERα gene. By leveraging the unique expression patterns of these mutations, the research aims to enhance the effectiveness of treatment and reduce tumor growth. The study includes preclinical models to evaluate the potential of these new compounds, particularly for patients with brain metastases.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with ERα-positive breast cancer, especially those with mutations in the ERα gene.
Not a fit: Patients with ERα-negative breast cancer or those who do not have breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with ERα-positive breast cancer, potentially overcoming resistance to current therapies.
How similar studies have performed: Previous research has shown promise in targeting oncogenic drivers in cancer, indicating that this approach could lead to significant advancements in treatment.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Boudreau, Matthew W — Dana-Farber Cancer Inst
- Study coordinator: Boudreau, Matthew W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.